Clinical factors and prognosis in non-small cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 5, 1999, Pages 453-457

  Martins, Sandro J ^a,b,c   Pereira, José Rodrigues ^a  

^a Instituto do Cancer Dr Arnaldo   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c NONE   (Brazil)

Author keywords

Chemotherapy; Non small cell lung cancer; Radiotherapy; Surgery; Survival analysis; Symptom

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; TAXANE DERIVATIVE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; DYSPNEA; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SUPERIOR CAVA VEIN SYNDROME; TREATMENT OUTCOME; UNDIFFERENTIATED CARCINOMA; WEIGHT REDUCTION;

ADULT; AGED; BRAZIL; CARCINOMA, NON-SMALL-CELL LUNG; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0033503005     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199910000-00006     Document Type: Article

References (28)

1. Fry WA, Menck HR, Winchester DP. The National Cancer Data Base Report on lung cancer. Cancer 1996;77:1947-55.
2. Silva PPA, Pereira JR, Ikari FK, Minamoto H. Câncer de pulmão e retardo no diagnóstico: análise de 300 casos. Rev Ass Med Brasil 1992;38:145-9.
3. Sridhar KS, Raub W Jr, Duncan RC, Hilsenbeck S, Richman SP. Lung carcinoma in 1336 patients. Am J Clin Oncol 1991;14:496-508.
4. Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol 1997;24:455-62.
5. Ramanathan RK, Belani CP. Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin Oncol 1997;24:440-54.
6. Ruckdeschel JC. Combined modality therapy of non-small cell lung cancer. Semin Oncol 1997;24:429-39.
7. Thatcher N, Niven RM, Anderson H. Aggressive vs. nonaggressive therapy for metastatic NSCLC. Chest 1996;109:87S-92S.
8. Asamura H, Naruke T. Lung carcinoma. In: Hernanek P, Gospodarowicz MK, Henson DE, Hutter RVP, Sobin LH, eds. Prognostic factors in cancer. Geneva: UICC, 1995;118-29.
9. Hilsenbeck SG, Raub WA Jr, Sridhar KS. Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol 1993;16:301-9.
10. Rosvold E. Prognostic factors for patients with non-small cell lung cancer. Curr Probl Cancer 1996;272-8.
11. Lutz ST, Huang DT, Ferguson CL, Kavanagh BD, Tercilla OF, Lu J. A retrospective quality of life analysis using the Lung Cancer Symptom Scale in patients treated with palliative radiotherapy for advanced non-small cell lung cancer, Int J Radiat Oncol Biol Phys 1997;37:117-22.
12. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 1996;77:834-42.
13. Campos-Filho N, Franco EL. Microcomputer-assisted univariate survival data analysis using Kaplan-Meier life table estimators. Comput Methods Programs Biomed 1988;27:223-8.
14. Cox DR. Regression models and life tables. J R Stat Soc 1972;34: 187-220.
15. Barkley JE, Green MR. Bronchioloalveolar carcinoma. J Clin Oncol 1996;14:2377-86.
16. Daly RC, Trastek VF, Pairolero PC, et al. Bronchoalveolar carcinoma: factors affecting survival. Ann Thorac Surg 1991;51:368-77.
17. Feldman ER, Eagan RT, Schaid DJ. Metastatic bronchioloalveolar carcinoma and metastatic adenocarcinoma of the lung: comparison of clinical manifestations, chemotherapeutic responses and prognosis. Mayo Clin Proc 1992;67:27-32.
18. Hsu CP, Chen CY, Hsu NY. Bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 1995;110:374-81.
19. Herbert ME, Lowe VJ, Hoffman JM, Patz EF, Anscher MS. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996;19:416-21.
20. Passlick B, Izbicki JR, Kubuschok B, Thetter O, Pantel K. Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. Ann Thorac Surg 1996;61:177-83.
21. Chen YM, Yang S, Perng RP, Tsai CM. Superior vena cava syndrome revisited. Jpn J Clin Oncol 1995;25:32-6.
22. Maddox AM, Valdivieso M, Lukeman J, et al. Superior vena cava obstruction in small cell bronchogenic carcinoma. Cancer 1983; 52:2165-72.
23. Sculier JP, Evans WK, Feld R, et al. Superior vena caval obstruction syndrome in small cell lung cancer. Cancer 1986;57:847-51.
24. Van Houtte P, Jager R, Lustman-Maréchal J, Kenis Y. Prognostic value of the superior vena cava syndrome as the presenting sign of small cell anaplastic carcinoma of the lung. Eur J Cancer 1980; 16:1447-50.
25. Würschmidt F, Bünemann H, Heilmann HP. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases, Int J Radiat Oncol Biol Phys 1995;33:77-82.
26. Pereira JR, Martins SJ, Cardenuto SL, Ikari FK, Nikaedo SM. Perfil clinico de pacientes com sindrome da veia cava superior por câncer de pulmão. Folha Médica (Brasil) 1996;113:171-7.
27. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. Cancer 1995;76: 593-601.
28. Wagner H Jr. Radiation therapy in the management of patients with unresectable stage IIIA and IIIB non-small cell lung cancer. Semin Oncol 1997;24:423-8.